Boehringer anti-clotting drug performs in Phase III

The race for a new anti-clotting therapy turned even hotter today as Boehringer Ingelheim announced that a late-stage study of its once daily pill dabigatran showed that the therapy is as effective as Lovenox injections for preventing blood clots after hip surgery. Boehringer has positioned the drug against Bayer's rivaroxaban, which demonstrated superiority to Lovenox after knee surgery. The clotting development race began after AstraZeneca failed to gain an approval for Exanta in 2004.

- see the release for more

Related Articles:
Pfizer, BMS report Phase II clotting trial success. Report
TransTech inks deal with Boehringer. Report
Boehringer wins Aptivus OK. Report